Fascioliasis: Clinical Trials

3 trials for Fascioliasis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 not yet recruiting, 1 unknown. 1 Phase 2, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 21Not yet recruiting 1
Phase 41Completed 1

Follow Fascioliasis: new trials by email Literature Review of Fascioliasis trials Research Report on Fascioliasis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis
Oxfendazole, Triclabendazole - Fascioliasis
Phase 2Not yet recruitingUniversidad Peruana Cayetano Heredia3362026-08-152026-06-03
Study of Safety, Tolerability and Clinical Outcomes of Egaten in Fascioliasis Patients (6 Years of Age or Older).
Egaten (Triclabendazole) 250 mg tablets - Fascioliasis
Phase 4CompletedNovartis Pharmaceuticals3012022-02-112026-10-06
Parasitological Evaluation of Fascioliasis in Clinically Suspected Patients .
Fascioliasis
UnknownAssiut University502019-09-012019-07-05

Broader conditions

Digestive System Diseases (3)  ·  Helminthiasis (3)  ·  Infections (3)  ·  Liver Diseases (3)  ·  Liver Diseases, Parasitic (3)  ·  Parasitic Diseases (3)  ·  Trematode Infections (3)

Interventions

Triclabendazole (2)  ·  oxfendazole (1)

Sponsors

Assiut University (1)  ·  Novartis Pharmaceuticals (1)  ·  Universidad Peruana Cayetano Heredia (1)

Countries

Egypt (2)  ·  Colombia (1)  ·  Peru (1)  ·  Turkey (Türkiye) (1)  ·  Vietnam (1)

Top investigators

Hector H Garcia, MD PhD (1)  ·  Lourdes Rodriguez, MD (1)  ·  Miguel M Cabada, MD MSc (1)  ·  Salma M Abdel-Rahman, prof (1)

NIH funding

U01AI155323 (1)